Public Release: 

Insilico to present latest advances in AI for drug discovery at R&D Data Intelligence Leaders Forum

InSilico Medicine, Inc.

IMAGE

IMAGE: Alex Zhebrak, Chief Technology Officer at Insilico Medicine presents "Next-Generation Artificial Intelligence for Drug Discovery " at The 6th Annual Life Science R&D Data Intelligence Leaders Forum in Basel, Switzerland.... view more 

Credit: Insilico Medicine

Thursday, January 17, 2019 - Insilico Medicine, a Rockville-based company developing the end-to-end drug discovery pipeline utilizing the next generation artificial intelligence, will present its latest results in modern and next-generation AI for Drug Discovery at the R&D Data Intelligence Leaders Forum in Basel, Switzerland, 24 of January.

Artificial Intelligence (AI) techniques, such as deep learning (DL) and reinforcement learning (RL) play a pivotal role in making the hunt for new pharmaceuticals quicker and more effective. At Insilico AI has been used as a powerful tool to identify targets for drug development, and with the ability to simulate and accelerate research processes, AI helps more drugs to be discovered and come to market quickly. The presentation will focus on the latest advances in artificial intelligence for discovery, development and real world evidence collection of drugs and geroprotectors.

"We are happy to present our work at the R&D Data Intelligence Leaders Forum, which gathers the key industry leaders. The topic of Next-Generation AI for Drug Discovery is rapidly gaining popularity, and we are happy to be at the leading edge of research and one of the innovation drivers in the area", says Alex Zhebrak, Chief Technology Officer at Insilico Medicine, Inc.

The 6th Annual Life Science R&D Data Intelligence Leaders Forum The "R&D Data Intelligence Leaders Forum" is the must attend event for the senior decision-makers, researchers and technologists, looking to make the shift towards an integrated R&D and data strategy and for those looking to improve their implementation of data-driven approaches to enhance R&D decision-making and intelligence. The Forum is held on 23-25 of January in Basel, Switzerland.

###

Insilico Medicine is regularly publishing research papers in peer-reviewed journals. The company was first to apply the generative adversarial networks (GANs) to the generation of the new molecular structures with the specified parameters and published a seminal peer-reviewed paper submitted in June 2016. The concept was further extended and augmented with advanced memory and reinforcement learning. One of the latest papers published in the Journals of Gerontology demonstrated the application of the deep neural networks to assessing the biological age of the patients. The latest special issue in Molecular Pharmaceutics featured several research papers by Insilico Medicine. Insilico published an overview of its results in aging research including the development of AI aging biomarkers, target identification, cross-species comparison and geroprotector discovery in Aging Research Reviews, one of the highest-impact journals in the field.

For further information, images or interviews, please contact:

Contact: Polina Firsanova

ai@pharma.ai

Website: http://insilico.com/

Official website of the conference:

https://www.nextlevells.com/events/r-d-data-intelligence-leaders-forum-2019

About Insilico Medicine, Inc

Insilico Medicine is an artificial intelligence company headquartered in Rockville, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists are dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine, and aging research.

Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com, the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. In 2018 it received the Frost & Sullivan 2018 North American Artificial Intelligence for Aging Research and Drug Development Award accompanied with the industry brief. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8. http://www.insilico.com

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.